- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1476-5551
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Molecular pathogenesis of disease progression in MLL-rearranged AML ; day:12 ; month:9 ; year:2018 ; pages:1-13
Leukemia ; (12.9.2018), 1-13
- Urheber
-
Kotani, Shinichi
- Beteiligte Personen und Organisationen
-
Yoda, Akinori
Kon, Ayana
Kataoka, Keisuke
Ochi, Yotaro
Shiozawa, Yusuke
Hirsch, Cassandra
Takeda, June
Ueno, Hiroo
Yoshizato, Tetsuichi
Yoshida, Kenichi
Nakagawa, Masahiro M.
Nannya, Yasuhito
Kakiuchi, Nobuyuki
Yamauchi, Takuji
Aoki, Kosuke
Shiraishi, Yuichi
Miyano, Satoru
Maeda, Takahiro
Maciejewski, Jaroslaw P.
Takaori-Kondo, Akifumi
Ogawa, Seishi
Makishima, Hideki
SpringerLink (Online service)
- DOI
-
10.1038/s41375-018-0253-3
- URN
-
urn:nbn:de:101:1-2018102900024324929111
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:56 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kotani, Shinichi
- Yoda, Akinori
- Kon, Ayana
- Kataoka, Keisuke
- Ochi, Yotaro
- Shiozawa, Yusuke
- Hirsch, Cassandra
- Takeda, June
- Ueno, Hiroo
- Yoshizato, Tetsuichi
- Yoshida, Kenichi
- Nakagawa, Masahiro M.
- Nannya, Yasuhito
- Kakiuchi, Nobuyuki
- Yamauchi, Takuji
- Aoki, Kosuke
- Shiraishi, Yuichi
- Miyano, Satoru
- Maeda, Takahiro
- Maciejewski, Jaroslaw P.
- Takaori-Kondo, Akifumi
- Ogawa, Seishi
- Makishima, Hideki
- SpringerLink (Online service)
Ähnliche Objekte (12)
SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML
Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML
RNA binding proteins in MLL-rearranged leukemia
Using genome editing to model MLL rearranged leukemias
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia
Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia
Mit AML assoziierte MLL-partielle Tandemduplikationen (MLL-PTD) sind in Stammzellen aus Nabelschnurblut lebenslang nachweisbar
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
Therapeutic strategies against hDOT1L as a potential drug target in MLL-rearranged leukemias
SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML
Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML
RNA binding proteins in MLL-rearranged leukemia
Using genome editing to model MLL rearranged leukemias
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia
Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia
Mit AML assoziierte MLL-partielle Tandemduplikationen (MLL-PTD) sind in Stammzellen aus Nabelschnurblut lebenslang nachweisbar
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
Therapeutic strategies against hDOT1L as a potential drug target in MLL-rearranged leukemias
SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML
Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML
RNA binding proteins in MLL-rearranged leukemia
Using genome editing to model MLL rearranged leukemias
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia
Targeting the histone H3 lysine 79 methyltransferase DOT1L in MLL-rearranged leukemias
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia
Mit AML assoziierte MLL-partielle Tandemduplikationen (MLL-PTD) sind in Stammzellen aus Nabelschnurblut lebenslang nachweisbar
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia